Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum BioVaxys Technology Corp. BVAXF


Primary Symbol: C.BIOV

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical... see more

Bullboard (CSE:BIOV)

View:
Post by moneywagonon Jan 20, 2022 10:59am

BIOV BEARS DON'T ACT LIKE A STUBBORN MULE~FEED DA BID~MOVEON

:>))) GOOD MORNING BIOV..entire health sector day 2 on a decline, resources are finally get a nice uptick, they're turn. Pay tience people every light is ON in every labratory, every scientist, ...more  
Post by moneywagonon Jan 19, 2022 2:37pm

BIOV TO BE HONEST IT'S A TREAT TO EAT SHARES DOWN HERE

It's simply the market nothing to do with BIOV...WE wait!!
Post by moneywagonon Jan 19, 2022 2:35pm

PFIZER'S NEW COVID-19 PILL WORKS AGAINST OMICRON IN LAB

Pfizer’s New Covid-19 Pill Works Against Omicron in Lab Three separate, unpublished lab studies indicate Paxlovid is effective against the variant despite its mutations  ...more  
Post by moneywagonon Jan 19, 2022 2:33pm

WHO IS WUXI BIOLOGICS

Vision & Mission Our Vision “Every drug can be made and every disease can be treated” by building an open-access platform with the most comprehensive capabilities and technologies ...more  
Post by moneywagonon Jan 19, 2022 2:31pm

REMEMBER BIOV PARTNER WUXI BIOLOGICS

NEWS PROVIDED BY BioVaxys Technology Corp.  Sep 14, 2021, 03:00 ET SHARE THIS ARTICLE   ...more  
Post by moneywagonon Jan 19, 2022 10:37am

BIOV I'M WITH FRANKMAN YAHOOO I GOT FILLED AGAIN@20

SUCKERS selling down here sheesh..I sat at @19 for so long and I missed the scraps sold @195 yesterday, but nothing pi$$es me off more than only a portion of my order filled and then sp takes off!! SO ...more  
Post by Rossaporinoon Jan 17, 2022 10:24pm

Report

https://www.businesswire.com/news/home/20220117005372/en/COVID-19-Enzyme-Immuno-AssayEnzyme-Linked-Immunosorbent-Assay-EIAELISA-Medical-Devices-Pipeline-Landscape-Report-2021---ResearchAndMarkets.com
Comment by frankmanon Jan 17, 2022 3:21pm

RE:With few shares selling guess I'll buy a few

Might hit .30 on the next bounce
Post by frankmanon Jan 17, 2022 2:32pm

Where did the sell side go?

Ask 0.25 9,000 1 0.24 12,000 1 0.235 1,000 1 0.23 4,000 1 0.225  ...more  
Post by frankmanon Jan 17, 2022 12:17pm

Asks to .27 Got yours yet?

Ask 0.27 13,000 1 0.255 3,000 1 0.25 9,000 1 0.24 12,000 1 0.235  ...more  
Post by frankmanon Jan 17, 2022 10:40am

Asks now.24 up

Ask 0.28 14,500 2 0.275 14,000 1 0.25 21,000 2 0.245 5,500 1 0.24  ...more  
Post by frankmanon Jan 17, 2022 10:24am

Bid ask

Ask 0.275 14,000 1 0.26 5,000 1 0.25 9,000 1 0.245 6,000 1 0.23  ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities